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Background: Early detection of drug resistance is one of the priorities of tuberculosis (TB) control programs as drug
resistance is increasing. New molecular assays are only accessible for a minority of the second line drugs and their
availability in high endemic settings is also hampered by high cost and logistic challenges. Therefore, we evaluated
a previously developed method for drug susceptibility testing (DST) including both first- and second line anti-TB
drugs for use in high endemic areas.
Results: Baseline mycobacterial isolates from 78 consecutive pulmonary TB patients from Addis Ababa, Ethiopia
who were culture positive for Mycobacterium tuberculosis at the end of a two-month directly observed treatment
short course (DOTS) were included. The isolates were simultaneously tested for isoniazid, rifampicin, ethambutol,
streptomycin, amikacin, kanamycin, capreomycin, ofloxacin, moxifloxacin, ethionamide and para-aminosalicylic acid
susceptibility using the indirect proportion method adopted for 24-well agar plates containing Middlebrook 7H10
medium. Applying the 24-well plate assay, 43 (55.1%) isolates were resistant to one or more of the first line drugs
tested (isoniazid, rifampicin and ethambutol). MDR-TB was identified in 20.5% of this selected group and there was
a perfect correlation for rifampicin resistance with the results from the genotype MTBDRplus assay. All isolates were
susceptible to aminoglycosides and fluoroquinolones in agreement with the genotype MTBDRsl assay. The only
tested second line drug associated to resistance was ethionamide (14.1% resistant). The method was reproducible
with stable results for internal controls (one multi-drug resistant (MDR) and one pan-susceptible strain (H37Rv) and
DST results could be reported at two weeks.
Conclusions: The 24-well plate method for simultaneous DST for first- and second line drugs was found to be
reproducible and correlated well to molecular drug susceptibility tests. It is likely to be useful in high-endemic areas
for surveillance as well as for the detection of second line drug resistance in targeted groups such as in those who
fail empirical MDR treatment.
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Tuberculosis (TB) remains one of the major public health
challenges, particularly in high endemic areas where there
is a growing and probably underestimated problem of re-
sistance to anti-TB drugs. Early detection of drug resis-
tance is one of the priorities of TB control programs [1].
Management of drug resistant TB has an important im-
pact for improved TB control by employing appropriate
multi-drug treatment regimens which are in turn based
on the national resistance epidemiology. However, repre-
sentative and continuous TB drug resistance surveillance
data is largely missing in low-income high endemic areas
partly due to poor laboratory facilities [2]. A national drug
resistance survey in Ethiopia conducted in 2005 reported
a multi-drug resistant (MDR)-TB rate of 1.6% among
newly diagnosed patients and 11.8% among retreatment
cases [3].
The increasing rate of resistance to the commonly
used anti-TB drugs causes an urgent need for accurate
and reproducible assays for second line drug susceptibil-
ity testing (DST) in high endemic areas [4]. Various DST
methods have been developed including phenotypic test-
ing based on the growth of the bacilli on drug contain-
ing solid or liquid medium [5] and genotypic detection
of resistance determining genes [6-8]. Molecular approa-
ches such as line probe assays and the GeneXpert MTB/
RIF (Cepheid, Inc. USA) present a significant advantage
mainly in terms of rapid diagnosis of MDR-TB and have
been recommended as initial diagnostic tests in individ-
uals at risk [7,9]. A drawback of such molecular based
methods is that they include only some of the first and
second line anti-TB drugs and that they are not suitable
for drug resistance surveillance studies as they only
include known drug resistance mutations. In contrast,
conventional broth- and agar-based methods have been
validated against clinical outcome at least for the first
line drugs and are established for most second line
drugs used although the breakpoints to predict clinical
susceptibility for some of those drugs are not as well
characterized [10].
In low income countries, phenotypic DST is com-
monly performed with conventional methods such as
the indirect proportion method on Löwenstein-Jensen
(LJ) or Middlebrook 7H10 agar media owing to the rela-
tively low cost. However, most of these conventional phe-
notypic methods require several weeks to months in order
to obtain results. In contrast to phenotypic methods, the
genotyping approaches of drug resistance detection are
rapid but have limited implementation in daily routine,
particularly in resource limited areas where the burden of
tuberculosis is substantial, due to their high cost and need
for continuous electric power supply [7].
The increasing trend of resistant TB in high ende-
mic areas with insufficient laboratory support [11] is acompelling reason to explore for alternative DST methods
for first and second line drugs in patients that are at high
risk of developing resistant TB. Effective management of
MDR and poly resistant TB under routine program condi-
tions requires assessment of drug resistance to both first
and second line drugs to provide the best therapy for the
patients and prevent transmission. Automated liquid cul-
ture systems, particularly the BACTEC MIGT 960, have
been recommended for DST of second line drugs [12].
Implementation of the liquid culture system in resource-
constrained settings is, nevertheless, impeded by the high
cost of laboratory infrastructures [13,14].
In this study we applied a previously described low
cost DST method which was slightly modified to suit
high endemic areas [15]. Our aim was to evaluate this
method adapted for 24-well plates containing 7H10




A total of 500 newly diagnosed smear positive pulmo-
nary TB patients were enrolled to receive standard ther-
apy against active tuberculosis consisting of isoniazid,
rifampicin, pyrazinamide and ethambutol daily under
supervision at the treatment center (St Peter’s TB Spe-
cialized Hospital, Addis Ababa, Ethiopia). Eighty baseline
isolates obtained upon clinical presentation from con-
secutive patients who were still culture positive at the
end of the second month of intensive treatment with the
four drugs were used for testing in the 24-well plate assay.
From all study participants, written, informed consent was
obtained.
All patients
Mycobacterial culture and typing
The Mycobacterial isolates were obtained by sputum
culture processed according to standard methods [16]
on LJ media (Sigma-Aldrich Chemical Co.) and were
confirmed as Mycobacterium tuberculosis (Mtb) on
DNA isolated from heat killed, culture positive samples
using RD9 typing which relies on analysis of species spe-
cific genomic deletions [17] and spoligotyping (data
not shown). Following genotypic identification, isolates
were sub-cultured on LJ and cultures grown within 2-3
weeks were used for susceptibility testing on 7H10 media
(Sigma-Aldrich Chemical Co.). Colonies were transferred
from LJ to plastic tubes containing 3 ml of distilled water
and glass beads (3 mm in diameter). The tubes were
shaken for 1 min and the suspension was then allowed to
settle for 15 min. The suspension was adjusted to a turbid-
ity equivalent to that of a 1.0 McFarland standard. Subse-
quently, 24-well plates were inoculated by adding 10 μl of
this bacterial suspension.
Figure 1 Outline of the template used for drug concentrations
and controls used in the 24-well plate. The template outlining
the distribution and concentrations (μg/ml) of the drugs used is
shown. (CC = Critical Concentration, Cont = Control).
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In each experimental batch, 10 DST 24-well plates were
prepared in the preceding day of inoculation. Thus, a
new batch of freshly prepared 24-well plates was used
within one day for 13 rounds of DST which included
H37Rv and the MDR control isolate. Dilutions of the an-
tibiotics were prepared to get the required antibiotic
concentrations. A volume of each antibiotic was mixed
with 7H10 medium in 50 ml Falcon tube in a water bath
to get the required drug concentration in the agar mix-
ture needed for 10 plates. The drug containing and the
drug free media were then manually transferred in 2.5 ml
amounts into the respective wells of the 24-well tissue cul-
ture plates. The plates were then left in the safety hood
until the agar was completely solidified and subsequently
sealed with Parafilm and stored at 4°C until used the
next day.
Drug susceptibility testing with the 24-well plate method
The drug susceptibility patterns of the clinical isolates
were determined using a modified indirect proportion
method adapted for 24-well agar plates containing 7H10
medium as previously described [15]. Compared to the
original method, no automatic dispenser was used and
the plates were prepared manually as described. The
plates were read at 2 weeks after inoculation by the same
evaluator (WW) as it was reported previously that the
MIC results could be reported at that time point [15].
Drug susceptibility was read by visual comparison of the
drug containing media (1:1 bacterial suspensions) with
the drug free control on which 1:100 bacterial suspen-
sions was inoculated. The growth was evaluated accord-
ing to the proportion method by comparing the 1:100
diluted control to the drug containing wells. The strain
was reported susceptible (S) if there was clearly more
growth in the 1:100 diluted control than in the drug
containing well with the critical concentration and re-
sistant (R) if there was more growth in the drug contain-
ing well than in the 1:100 control.
The method was also modified for the simultaneous
testing of first and second line anti-TB drugs (Sigma-
Aldrich Chemical Co. St. Louis, MO, USA) allowing
MIC testing for some of the most important drugs (INH,
AMK and OFL) currently available in the setting. Add-
itionally, conventional susceptibility testing was based on
currently recommended breakpoints (critical concentra-
tions). Thus, the following concentrations were chosen:
isonicotinic acid hydrazide (INH), 0.064, 0.125, 0.2 and
1.0 μg/ml; rifampicin (RIF), 1.0 μg/ml; ethambutol (EMB),
4.0, 5.0 and 8.0 μg/ml; streptomycin (STM), 2.0 μg/ml;
capreomycin (CAP), 10.0 μg/ml; amikacin (AMK), 0.25,
0.5, 1.0 and 2.0 μg/ml; kanamycin (KAN), 5.0 μg/ml; ethi-
onamide (ETH), 2.0 and 5.0 μg/ml; p-aminosalicylic acid
(PAS), 2.0 μg/ml; ofloxacin (OFL), 0.125, 0.25, 0.5, 1.0 and2.0 μg/ml and moxifloaxin (MOX), 0.5 μg/ml [10,18]. The
template used is shown in Figure 1. Drug concentrations
other than the critical concentrations were used for some
of the above anti-TB drugs for quality control purpose.
Growth with the following critical concentrations (CC)
of the test drugs defined resistance: 0.2 μg/ml INH,
1.0 μg/ml RIF, 5 μg/ml EMB, 2.0 μg/ml STM, 10.0 μg/ml
CAP, 5.0 μg/ml KAN, 5.0 μg/ml ETH, 2.0 μg/ml PAS,
2.0 μg/ml OFL and 0.5 μg/ml MOX [10,18,19]. For AMK
where no CC was defined by WHO at the time of the
study for 7H10 medium, the previously suggested critical
concentration based on the wild type distribution was
applied (1.0 μg/ml AMK) [19].
Hain GenoType MTBDRplus
The evaluation of the 24-well plate method in detecting
MDR isolates was also compared with the GenoType
MTBDRplus. For aminoglycosides and fluoroquinolones
the phenotypic results from the 24 well assay was com-
pared to the HAIN MTBDRsl assay through the detec-
tion of mutations in the gyrA and rrs genes, respectively.
Essentially, the MTBDRplus and MTBDRsl assays share
the same procedure (GenoType® MTBDRplus, GenoType®
MTBDRsk Hain Life science GmbH, Germany). The
MTBDRplus test is based on PCR amplification of specific
regions of RIF and INH resistance conferring genes, rpoB,
katG and inhA followed by reverse hybridization of ampli-
cons to specific probes pre-blotted to membrane strips
and colorimetric detection of the key mutations associated
with RIF and INH resistance [20].
Quality control
Parallel to all 13 sets of test batches, the standard pan
susceptible strain, H37Rv (ATCC 27249) where MIC le-
vels have previously been established for the major first-
and second line drugs [10,19,21] were inoculated on
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A clinical MDR-TB strain sent to Ethiopian Health and
Nutritional Research Institute (EHNRI) (the national ref-
erence laboratory) for proficiency testing with confirmed
resistance to INH and RIF was also included as positive
control. The critical concentrations applied were accord-
ing to the recommendations from the WHO [10,18].
Data analysis
Analysis was performed using Graph Pad prism 5. Signifi-
cant differences in proportions between different groups
were assessed using Pearson’s Chi2 test with p ≤ 0.05 con-
sidered significant.
Ethical statement
Approval was obtained from the ethical review committee
of the Armauer Hansen Research Institute (AHRI)/All
Africa Leprosy, Tuberculosis and Rehabilitation Training
Centre (ALERT), Addis Ababa, Ethiopia. Written, in-
formed consent was obtained from all study participants.
Results
Quality control
The evaluation of the 24-Well Plate Assay in identifying
resistant and susceptible isolates and in determining
MIC values of the anti-TB drugs was assured using in-
ternal quality controls. The pan susceptible H37Rv (ATCC
27294) strain (n = 13) and one clinical MDR strain
(n = 11) were included as internal controls for all drugs
and additionally the MIC value of INH, AMK and OFL
were evaluated (Table 1). The result showed a very low
MIC variation between experiments for H37Rv with one
dilution step deviation at two and three experimental oc-
casions for INH and OFL, respectively out of 13 separateTable 1 MIC distributions and intra laboratory variations for
Test batch MIC (μg/ml) for H37Rv
INH AMK OFL
01 0.125 0.5 0.5
02 0.125 0.5 0.5
03 0.125 0.5 0.5
04 0.125 0.5 0.5
05 0.125 0.5 1.0
06 0.125 0.5 1.0
07 0.125 0.5 1.0
08 0.125 0.5 0.5
09 0.125 0.5 0.5
10 0.2 0.5 0.5
11 0.2 0.5 0.5
12 0.125 0.5 0.5
13 0.125 0.5 0.5
(ND, no data; QC = Quality control).experiments and batches of 24-well plates. The same
MIC-level at 1.0 μg/ml was detected for AMK in all 13
rounds. Considering the MDR clinical strain used as a
control, there was a complete agreement in the MIC level
of INH, AMK and OFL and drug susceptibility results
in each test round (n = 11) including STM, ETH, CAP,
AMK, PAS, KAN and EMB (Table 1). Thus, the reprodu-
cibility of the 24-well plate method or H37Rv and the
MDR clinical strain for all included drugs was excellent.
Evaluation of the 24 well DST method for the first
line drugs
Assessment of drug resistance by the 24-well plate assay
was performed on 78 isolates that were confirmed to be
Mtb by RD9 and spoligotyping. The remaining two
non-tuberculous mycobacterial (NTM) isolates were
not included in the final analysis of drug resistance. A
representative result from a DST round is presented in
Figure 2. The proportion of any type of drug resistance
among the clinical isolates was 55.1% (43/78). The high-
est level of drug resistance (36/78, 46.2%) was observed
for STM followed by INH and EMB with a proportion
of 39.7% (31/78) and 37.2% (29/78), respectively. MDR-TB
was detected in 20.5% of the isolates (16/78). All TB
Patient infected with strains resistant to RIF were also re-
sistant against INH and confirmed as MDR-TB.
Correlation between GenoType MTBDR and the
phenotypic DST assay
The evaluation of the 24 well plate method showed full
concordance to HAIN MTBDRplus in detecting MDR-TB.
However, discrepancies were observed between the two
methods in detecting isolated INH drug resistance. Seven
more isolates (31/78 vs 24/78) were identified as INHisoniazid (INH), amikacin (AMK) and ofloxacin (OFL)















Figure 2 Example of a typical readout for drug susceptibility
testing in the 24-well plate. Figure 2 shows a typical DST result
applying the template used in Figure 1 with a standard inoculum of
10 μl at a turbidity of a 1.0 McFarland standard. This isolate was
found to be resistant to INH, EMB, STM and ETH. The MIC for INH
is >1.0 μg/ml, for AMK≤ 0.125 μg/ml and for OFL = 0.25 μg/ml.
(CC = Critical Concentration, Cont = Control).
Figure 3 Minimal inhibitory concentration (MIC) distribution of
amikacin. MIC distributions for the second line drug amikacin
among the 78 Mycobacterium tuberculosis isolates. (MIC =Minimal
inhibitory concentration, AMK = Amikacin.
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MTBDRplus test (Table 2). Second line drug susceptibil-
ity patterns determined by the 24-well plate assay were
also compared with GenoType MTBDRsl for aminoglyco-
sides and fluoroquinolones. This analysis showed that that
all the sixteen MDR isolates were detected as susceptible
for these two classes of second line drugs by both tests.
Low prevalence of resistance to 2nd line drugs among
patients culture positive at 2 months of treatment
Resistance to the major second line drugs was also de-
termined together with first line drugs on the 24 well
plates. It was found that all isolates including the MDR
cases were susceptible to these drugs except for ethion-
amide where 14.1% of the isolates were resistant. MIC
determination of OFL as well as AMK showed that all
clinical isolates had MIC levels clearly below the critical
concentrations (Figures 3 and 4). Out of the 16 MDR-TB
cases, 37.5% were ethionamide resistant. However, noTable 2 Pattern of drug resistance to the major first- and
second line drugs











INH 31/78 (39.7%) 24/78 (30.7%) AMK 0
RMP 16/78 (20.5%) 16/78 (20.5%) KAN 0
EMB 29/78 (37.2%) CAP 0
STM 36/78 (46.2%) ETH 11/78 (14.1%)
PAS 0
OFL 0
MOX 0MDR strain was resistant to fluoroquinolones and/or
aminoglycosides and thus no XDR-TB was detected which
was also confirmed by the MTBDRsl assay.
Discussion
In this study we show the usefulness of the 24-well plate
assay for drug susceptibility testing of Mycobacterium
tuberculosis in resource limited settings. The method is
suitable for clinical laboratories with low-cost laboratory
materials and reagents and is easily standardized. In our
study, test results were available, on average, after 12 days
of incubation which is significantly lower than the repor-
ting time in LJ media which is about six weeks [22]. TheFigure 4 Minimal inhibitory concentration (MIC) distribution of
ofloxacin. MIC distributions for the second line drug ofloxacin
among the 78 Mycobacterium tuberculosis isolates. (MIC =Minimal
inhibitory concentration, OFL = Ofloxacin.
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high endemic areas because of its low cost and although
the 24-well method is slightly more expensive due to the
use of 7H10 medium, it is still less expensive and re-
source demanding than the routine liquid based and mo-
lecular biology based methods. An estimated cost per
sample for the 24-well plate assay is 5 Euros per plate
where up to 22 drugs could be analyzed [15]. Other pre-
viously described low-cost methods suitable for high
endemic areas are the microscopic-observation drug sus-
ceptibilty (MODS) and thin layer agar (TLA) assays but
data for second line drugs are limited [23,24]. A com-
monly acknowledged limitation of such assays including
the 24-well plate assay is the introduction of increased
variation under routine conditions due to lack of the stan-
dardization which has been done for routine methods like
BACTEC MGIT 960. Rapid molecular techniques are also
increasingly available for detecting anti-TB drug resist-
ance. However, such approaches require expensive equip-
ment and reagents which could not be widely applied in
high endemic areas and they are limited to commonly
known resistance mutations. The 24-well plate method is
a phenotypic assay with the potential to determine full
DST panels including second line drugs at a substantially
lower cost. The assay may also be tailored to suit local
treatment traditions in terms of which drugs that are in-
cluded. In the current study we primarily aimed at includ-
ing the current critical concentration for the included
first- and second line drugs. Secondly we prioritized short
MIC-series for important drugs available and in use in the
study setting at the time of the study (INH, AMK and
OFL) as the MIC level may be important to consider in in-
dividualized dosing strategies for patients with XDR TB.
Thus, the concentrations used for testing in this study
apart from the current critical concentration may need re-
vision according to the availability of the drugs and the na-
tional recommendations for the use of second line drugs.
In this perspective, MIC testing in future studies should
probably be preferred for newer generation fluoroquino-
lones such as MOX or LEV rather than OFL.
Limitations of our study include the relatively few sam-
ples and that only one center was involved. Moreover, the
inclusion of quality control strains exhibiting resistance to
the second line drugs would be an important step in the
development of the method. We find it assuring in terms
of quality control and reproducibility for the second line
drugs that there was perfect agreement in the H37Rv MIC
distribution within 13 separate rounds of testing for the
fluoroquinolones and aminoglycosides (Table 1) and a
variation within one MIC dilution step compared to previ-
ous studies [10,19,21]. Both the susceptible control strain
(H37Rv) and the MDR clinical strain showed very stable
MIC levels for INH, AMK and OFL which indicates a very
high stability that is likely also to include slightly higherMIC levels observed in resistant strains. Additionally, the
classification of the other drugs was also stable for 13
rounds.
We also evaluated the 24-well plate method with the
GenoType MTBDRplus in detecting resistance to RIF
and INH. The two DST methods had 100% concordance
in identifying MDR isolates confirming the overall per-
formance of the 24-well plate method for detection of
MDR-TB. However, we observed discrepant DST results
between the 24-well plate assay and the Hain MTBDRplus
test for INH where 7 (9%) of INH resistant isolates at the
critical concentration of 0.2 μg/ml were detected as sus-
ceptible by the GenoType MTBDRplus technique. As pre-
viously reported, this is probably due to the known fact
that not all genetic alterations causing INH resistance are
present in the Hain assay, which also highlights one major
drawback of the molecular assays [25]. The GenoType
MTBDRplus technique could be used as a supplement to
the low cost conventional 24-well plate method for MDR
case detection [26]. A strategy for combining the use of
these techniques could be to employ a rapid molecular
assay such as the Hain or GeneXpert in patients who re-
main smear or culture positive at week 8 in order to rap-
idly identify MDR cases in need for a rapid shift to an
empirical MDR regimen and then use the 24-well assay to
screen such isolates for 2nd line drug resistance to provide
the best possible definite treatment.
The 24-well method may also be suitable when pro-
cessing large number of samples like in the case of drug
resistance surveillance studies where simultaneous testing
of first and second line drugs may be required. It allows
producing many plates a day and processing hundreds of
isolates. The assay is easily manageable during inoculation,
incubation and reading. Overall, it could be an alternative
to more resource demanding liquid culture based DST
methods. The introduction of the MDR-TB management
system in high endemic areas such as Ethiopia makes such
assays useful for early identification of multi drug re-
sistance allowing prompt initiation of treatment with sub-
sequent early identification of MDR-TB as a cause of
treatment failure.
The proportion of first line anti-TB drug resistance
among the study participants is markedly high. Resistance
to one or more first line anti-TB drugs was observed in 43
(55.1%) of the 78 consecutive clinical isolates. The overall
rate is higher than some of the resistance rates reported
from various regions in Ethiopia [27-31]. However, the
rate of MDR-TB in our sample of newly diagnosed TB pa-
tients (16/500; 3.2%) could be compared to the 2005 na-
tional estimate at 1.6% [3]. The discrepancy could be due
to the study setting in which our isolates were collected.
All the 80 samples were selected from 500 previously un-
treated cases in total based on culture positivity at two
months after taking the first line drug treatment. In vitro
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simultaneous to the first line drugs. The use of the second
line drugs in Ethiopia so far has been low which means
that there has been a low selective pressure for second line
drug resistance. Our finding revealed that all isolates were
susceptible to the major second line drugs except for ETH
where we observed 14.1% resistance. A study done in the
Northwest region of Ethiopia has also reported the lack of
second line drug resistance [30]. In the study of Agonafir
[32], ETH resistance was observed in 65.2% of 46 MDR-
TB isolates which could be compared to a 37.5% rate of
ETH resistance among the MDR-TB cases in the present
study. The relatively high rate of ETH drug resistance
could partly be due to the occurrence of cross resistance
between this drug and INH. In a study done in South
Africa, ETH co-resistance was observed in 19 of the 39
INH resistant Mtb isolates [33]. In our report, 41.7%
(10/24) of INH resistant cases screened by the 24-well
plate assay were also ETH resistant. Over all, the findings
on second line drug resistance suggest that so far, there
is a very low rate of second line drug resistant isolates
in Ethiopia. Inadequately treated patients are at high
risk of spreading drug resistant strains. With the intro-
duction of MDR-TB treatment, it is important to con-
tinuously screen for second line drug resistance in high
endemic areas as the number of cases and the risk of
rapidly spreading resistant isolates increases due to in-
adequate treatment.
Conclusions
We conclude that the 24 well plate method for simultan-
eous testing of several first- and second line drugs is a
rapid, relatively inexpensive and stable method for the
detection of drug resistant Mycobacterium tuberculosis
isolates.
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